0001104659-21-000926.txt : 20210105 0001104659-21-000926.hdr.sgml : 20210105 20210105161525 ACCESSION NUMBER: 0001104659-21-000926 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20201229 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210105 DATE AS OF CHANGE: 20210105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IDERA PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000861838 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 043072298 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31918 FILM NUMBER: 21505665 BUSINESS ADDRESS: STREET 1: 505 EAGLEVIEW BOULEVARD STREET 2: SUITE 212 CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 4843481600 MAIL ADDRESS: STREET 1: 505 EAGLEVIEW BOULEVARD STREET 2: SUITE 212 CITY: EXTON STATE: PA ZIP: 19341 FORMER COMPANY: FORMER CONFORMED NAME: HYBRIDON INC DATE OF NAME CHANGE: 19951211 8-K 1 tm211584d1_8k.htm FORM 8-K
0000861838 false 0000861838 2020-12-29 2020-12-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): January 5, 2021 (December 29, 2020)

 

Idera Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

(State or Other

Jurisdiction of

Incorporation)

001-31918

(Commission File

Number)

04-3072298

(I.R.S. Employer

Identification No.)

 

505 Eagleview Blvd., Suite 212    
Exton, Pennsylvania   19341
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (484) 348-1600

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b)).
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c)).

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Common Stock, par value $0.001 per share   IDRA   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

As reported on a Form 8-K filed with the Securities and Exchange Commission on November 17, 2020, Idera Pharmaceuticals, Inc. (the “Company”) previously announced that R. Clayton Fletcher retired from his role as the Company’s Senior Vice President of Business Development and Strategic Planning, effective December 31, 2020.

 

On December 29, 2020 (the “Effective Date”), Company entered into a consulting services agreement (the “Consulting Agreement”) with Mr. Fletcher. The Consulting Agreement terminates one year following the Effective Date and provides for aggregate payments to Mr. Fletcher of up to $180,000, to be paid in equal monthly installments over the term of the Consulting Agreement. The Consulting Agreement also includes confidentiality and non-solicitation restrictions.

 

The foregoing description of the Consulting Agreement is qualified in its entirety by reference to the Consulting Agreement filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

 

Item 9.01.Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit

Number

 

Description

   
10.1   Consulting Agreement, dated December 29, 2020, between the Company and R. Clayton Fletcher. 
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

       
  IDERA PHARMACEUTICALS, INC.
     
Dated: January 5, 2021 By:   /s/ Bryant D. Lim
     

Bryant D. Lim

Senior V.P., General Counsel

 

 

 

EX-10.1 2 tm211584d1_ex10-1.htm EXHIBIT 10.1

 

Exhibit 10.1

 

CONSULTING SERVICES AGREEMENT

 

 

THIS CONSULTING SERVICES AGREEMENT (the “Agreement”) is made and entered into on December 29, 2020 (the “Effective Date”) by and between Idera Pharmaceuticals, Inc., having a place of business at 505 Eagleview Boulevard, Suite 212, Exton, Pennsylvania 19341, USA (hereinafter referred to as “Idera”) and Hilltop Consulting, LLC, having a place of business located at [ADDRESS] (hereinafter referred to as the “Consultant”). Idera and Consultant may be referred to herein individually as a “Party” and collectively as the “Parties.”

 

BACKGROUND

 

WHEREAS, Idera wishes to engage the Consultant to provide the Services described herein and Consultant agrees to provide the Services for the compensation and otherwise in accordance with the terms and conditions contained in this Agreement.

 

NOW THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, Idera and the Consultant, intending to be legally bound, agree to the terms set forth below.

 

1.TERM.

 

Commencing as of the Effective Date, and continuing for a period of one (1) year (the “Term”), unless earlier terminated pursuant to Section 5 hereof, Consultant agrees that it will serve as a consultant to Idera. This Agreement may be renewed or extended for any period as may be agreed in writing by the Parties.

 

2.SERVICES.

 

(a)Consultant’s duties and responsibilities shall be to provide services related to business development activities, ongoing advice to the Company, and such other consulting services as the parties may mutually agree in connection with Idera’s business requirements (the “Services”).

 

(b)The Consultant agrees that during the Term it is able and willing to devote the time necessary to complete the Services in a professional manner.

 

(c)Consultant represents and warrants to Idera that it is under no contractual or other restrictions or obligations that are inconsistent with the execution of this Agreement, or that will interfere with the performance of the Services. Consultant represents and warrants that the execution and performance of this Agreement will not violate any policies or procedures of any other person or entity for which it performs Services concurrently with those performed herein.

 

(d)In performing the Services, Consultant shall comply, to the best of its knowledge, with all business conduct, regulatory, ethical, and health and safety guidelines established by any governmental authority with respect to Idera’s business.

 

Confidential – Consulting AgreementPage -1-

 

 

(e)Indemnification. Idera hereby agrees to defend, hold harmless and indemnify Consultant, and its directors, officers and employees (the “Indemnitees”) from and against any and all liabilities, expenses and/or losses, including reasonable legal expenses and attorneys’ fees (collectively “Losses”) resulting from Third Party suits, claims, actions and demands to the extent that they arise or result from the Services performed pursuant to this Agreement.

 

3.CONSULTING FEE.

 

Subject to the provisions hereof, Idera shall pay Consultant the following:

 

(a)A rate of $15,000 per month (30 hours per month), to be paid on or within the first five (5) business days of the applicable month.

 

(b)The aggregate amount paid hereunder shall not exceed $180,000 without Idera’s written approval.

 

(c)Consultant shall be entitled to prompt reimbursement for all pre-approved reasonable expenses incurred in the performance of the Services, upon submission and approval of written statements and receipts in accordance with the then regular procedures of Idera, which are attached hereto as Exhibit A.

 

4.INDEPENDENT CONTRACTOR.

 

Consultant agrees that all Services will be rendered by it as independent contractor and that this Agreement does not create an employer-employee relationship between Consultant and Idera. Consultant shall have no right to receive any employee benefits including, but not limited to, health and accident insurance, life insurance, sick leave, and/or vacation time. Consultant agrees to pay all taxes including, self-employment taxes due in respect of the Consulting Fee and to indemnify Idera in the event Idera is required to pay any such taxes on behalf of Consultant.

 

5.EARLY TERMINATION.

 

(a)If Consultant: (i) voluntarily ceases performing the Services; (ii) becomes physically or mentally unable to perform the Services; or (iii) is terminated for cause, then, in each instance, the Consulting Fee shall cease and terminate as of such date. Any termination “For Cause” shall be made in good faith by Idera.

 

(b)This Agreement may be terminated without cause by either Party upon not less than thirty (30) days prior written notice by either Party to the other.

 

(c)Upon termination under Sections 5(a) or 5(b), neither Party shall have any further obligations under this Agreement, except for the obligations which by their terms survive this termination as noted in Section 18 hereof. Upon termination and, in any case, upon Idera’s request, Consultant shall immediately return to Idera all Confidential Information, as hereinafter defined, and all copies thereof.

 

Confidential – Consulting AgreementPage -2-

 

 

6.RESTRICTED ACTIVITIES.

 

During the Term and for a period of one (1) year thereafter, Consultant will not, directly or indirectly:

 

(a)solicit or request any employee of or consultant to Idera to leave the employ of or cease consulting for Idera;

 

(b)solicit or request any employee of or consultant to Idera to join the employ of, or begin consulting for, any individual or entity that researches, develops, markets or sells products that compete with those of Idera;

 

(c)solicit or request any individual or entity that researches, develops, markets or sells products that compete with those of Idera, to employ or retain as a consultant any employee or consultant of Idera; or

 

(d)induce or attempt to induce any supplier or vendor of Idera to terminate or breach any written or oral agreement or understanding with Idera.

 

7.PROPRIETARY RIGHTS.

 

(a)Definitions. For the purposes of this Section 7, the terms set forth below shall have the following meanings:

 

(i)Discoveries. If Consultant makes or assists in making any invention, discovery, innovation, improvements or ideas conceived in connection with the Services hereunder, whether patentable or not (collectively, “Discovery”), Consultant will immediately inform Idera in writing. Consultant agrees to not reduce such Discovery to practice, either actually or constructively, during the term of the Services, except as directed by Idera. In the event that such Discovery is constructively or actively reduced to practice either by Consultant or Idera during the Term of this Agreement, the Discovery will be Idera’s property, and title to the Discovery will vest in Idera or in Idera’s nominees, successors or assigns. Consultant will assign, and hereby assigns, to Idera all its rights, title and interest in and to any Discovery without any consideration beyond what is provided for by this Agreement. Consultant will execute all documents necessary to protect the interest of Idera in each such Discovery. Consultant will provide assistance as needed in publishing or protecting such Discovery by patent or otherwise in any and all countries, including in any patent office proceeding or litigation involving such Discovery.

 

Confidential – Consulting AgreementPage -3-

 

 

(ii)Copyrights. Any copyrightable work Consultant creates in the performance of the Services hereunder is a “work made for hire”, whether published or not (hereinafter “Work Product”). Idera will have all rights to and in such work, and it shall be Idera’s property. Consultant will assign, and hereby assigns, to Idera, without further compensation, all of its rights, title and interest in and to any copyrightable Work Product. Consultant agrees to execute any documents of assignment that may be required to vest ownership of the copyright in Idera. Consultant may not publish on any matter arising from the Services without first obtaining written permission from Idera.

 

(iii)Confidential Information. For the purposes of this Agreement, Confidential Information shall mean and collectively include: all information relating to the business, plans, and/or technology of Idera including, but not limited to technical information including inventions, methods, plans, processes, specifications, characteristics, assays, raw data, scientific preclinical or clinical data, records, databases, formulations, clinical protocols, equipment design, know-how, experience, and trade secrets; developmental, marketing, sales, customer, supplier, consulting relationship information, operating, performance, and cost information; computer programming techniques whether in tangible or intangible form, and all record bearing media containing or disclosing the foregoing information and techniques including, written business plans, patents and patent applications, grant applications, notes, and memoranda, whether in writing or presented, stored or maintained in or by electronic, magnetic, or other means.

 

Notwithstanding the foregoing, the term “Confidential Information” shall not include any information that: (a) can be demonstrated to have been in the public domain or was publicly known or available prior to the date of the disclosure to Consultant; (b) can be demonstrated in writing to have been rightfully in the possession of Consultant prior to the disclosure of such information to Consultant by Idera; (c) lawfully becomes part of the public domain or publicly known or available by publication or otherwise, not due to any unauthorized act or omission on the part of Consultant; or (d) is supplied to Consultant by a third party without binder of secrecy, so long as that such third party has no obligation to Idera or any of its affiliated companies to maintain such information in confidence.

 

Confidential Information may be disclosed to the extent that it is required by any law, regulation, or order of court to be disclosed. Prior to disclosing proprietary or Confidential Information of Idera, Consultant agrees that it will provide Idera with prompt written notice of such request or requirement prior to such disclosure so that Idera may seek a protective order or other appropriate remedy. If such protective order or other remedy is not obtained or Idera grants a written waiver hereunder, the Consultant may furnish only that limited portion of the Confidential Information which the Consultant is legally compelled to disclose or else stand liable for contempt or suffer other material censure or penalty; provided, however, that the Consultant shall use its best efforts to obtain reliable assurance that confidential treatment will be accorded the Confidential Information so disclosed.

 

Confidential – Consulting AgreementPage -4-

 

 

(b)Securities Law. Consultant hereby acknowledges that he is aware that Idera’s Confidential Information may include material, non-public information and that the United States securities laws impose restrictions on trading securities when in possession of such information and on communicating such information to any other person when it is reasonably foreseeable that such person is likely to trade in such securities.

 

(c)Non-Disclosure to Third Parties. Except as may be required by Consultant for the sole purpose of performing the Services, Consultant shall not, at any time now or in the future, directly or indirectly, use, publish, disseminate or otherwise disclose any Confidential Information or Concepts and Ideas to any third party without the prior written consent of Idera, which consent may be denied in each instance and all of the same, together with publication rights, shall belong exclusively to Idera.

 

(c)Idera Property. All documents, diskettes, tapes, procedural manuals, guides, specifications, plans, drawings, designs and similar materials, lists of present, past or prospective customers, customer proposals, invitations to submit proposals, price lists and data relating to the pricing of Idera' products and services, records, notebooks, and all other materials containing Confidential Information or information about Discoveries or Work Product (including all copies and reproductions thereof), that come into Consultant’s possession or control by reason of Consultant’s performance of the relationship, whether prepared by Consultant or others: (a) are the property of Idera, (b) will not be used by Consultant in any way other than in connection with the performance of the Services, (c) will not be provided or shown to any third party by Consultant, (d) will not be removed from Idera's or Consultant’s premises (except as Consultant's Services require), and (e) at the termination (for whatever reason), of Consultant's relationship with Idera, will be left with, or forthwith returned by Consultant to Idera. No license or conveyance of any ownership rights to the Consultant is granted or implied under this Agreement.

 

8.EQUITABLE RELIEF.

 

Consultant agrees that any breach of Sections 6 and 7 above by it would cause irreparable damage to Idera and that, in the event of such breach, Idera shall have, in addition to any and all remedies of law, the right to an injunction, specific performance or other equitable relief to prevent the violation or threatened violation of Consultant’s obligations hereunder.

 

9.WAIVER.

 

Any waiver by Idera of a breach of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach of the same or any other provision hereof. All waivers by Idera shall be in writing.

 

Confidential – Consulting AgreementPage -5-

 

 

10.SEVERABILITY; REFORMATION.

 

In case any one or more of the provisions or parts of a provision contained in this Agreement shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provision or part of a provision of this Agreement; and this Agreement shall, to the fullest extent lawful, be reformed and construed as if such invalid or illegal or unenforceable provision, or part of a provision, had never been contained herein, and such provision or part reformed so that it would be valid, legal, and enforceable to the maximum extent possible. Without limiting the foregoing, if any provision (or part of provision) contained in this Agreement shall for any reason be held to be excessively broad as to duration, activity or subject, it shall be construed by limiting and reducing it, so as to be enforceable to the fullest extent compatible with then existing applicable law.

 

11.ASSIGNMENT.

 

Idera shall have the right to assign its rights and obligations under this Agreement to a party which assumes Idera' obligations hereunder. Consultant shall not have the right to assign its rights or obligations under this Agreement without the prior written consent of Idera, which consent may be withheld. This Agreement shall be binding upon and inure to the benefit of Consultant’s successors, permitted assigns and, in the case where Consultant is an individual, heirs and legal representatives in the event of his/her death or disability.

 

12.USE OF NAMES.

 

Consultant shall not use the name of Idera for any purpose without obtaining Idera’s prior written approval thereof. Idera may use the name of Consultant for activities related to its standard business operations, which may include press releases and other public announcements.

 

13.HEADINGS.

 

Headings and subheadings are for convenience only and shall not be deemed to be a part of this Agreement.

 

14.AMENDMENTS.

 

This Agreement may be amended or modified, in whole or in part, only by an instrument in writing signed by the Parties.

 

Confidential – Consulting AgreementPage -6-

 

 

15.NOTICES.

 

Any notices or other communications required hereunder shall be in writing and shall be deemed given when delivered in person or when mailed, by certified or registered first class mail, postage prepaid, return receipt requested, addressed to the Parties at their addresses specified in the preamble to this Agreement or to such other addresses of which a Party shall have notified the others in accordance with the provisions of this Section 15.

 

16.COUNTERPARTS.

 

This Agreement may be executed in two or more counterparts, each of which shall constitute an original and all of which shall be deemed a single agreement.

 

17.GOVERNING LAW.

 

This Agreement shall be construed in accordance with and governed for all purposes by the laws of the Commonwealth of Pennsylvania, without giving effect to conflict of laws provisions.

 

18.SURVIVAL.

 

The provisions of Sections 6, 7, 8, 9, 10, 15, 17 and 18 of this Agreement shall survive the expiration of the Term or the termination of this Agreement. This Agreement supersedes all prior agreements, written or oral, between Idera and Consultant relating to the subject matter of this Agreement.

 

 

[Signature Page To Follow]

 

Confidential – Consulting AgreementPage -7-

 

 

 

       IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the Effective Date. 

 

Idera Pharmaceuticals   Hilltop Consulting, LLC
         
By: /s/ Vincent J. Milano   By: /s/  Robert C. Fletcher
Vincent J. Milano   Robert C. Fletcher
     
Date: December 29, 2020   Date: December 29, 2020

 

Confidential – Consulting AgreementPage -8-

 

 

Exhibit A

 

Idera Pharmaceuticals, Inc. Travel Policy (POLICY NO. 217)

 

TRAVEL & ENTERTAINMENT

 

PURPOSE:To establish guidelines for Company travel and entertainment and to ensure travel is consistent with Idera’s business objectives.

 

SCOPE:All Idera employees, directors and consultants (“Employees”).

 

POLICY:Idera will reimburse Employees who travel on approved Company business for all necessary reasonable business expenses. However, in no event will reimbursement exceed actual expenses. Neither luxury, nor sub-standard modes of transportation and accommodations should be used.

 

PROCEDURE FOR TRAVEL:

 

Employees are expected to pay for their travel with personal credit cards or cash. Employees are expected to pay their own credit card bill and any late fees or finance charges are the responsibility of the Employee. Any credit card rewards from use of the card belong to the Employee.

 

PROCEDURE FOR REIMBURSEMENT:

 

1.Upon return from your pre-approved business related travel, Idera requires the Employee to submit an original travel and expense report with the business purpose identified. Travel should be via the lowest cost alternative within reason. All original receipts are requested but receipts for expenses greater than $20 USD are required. Expense reports must be submitted in a timely fashion. Please attach original receipts to your travel and expense report and complete within five (5) business days from your return. Deduct any personal expenses. Any receipts not provided must be noted on the travel and expense report. If business travel was overseas, convert to U.S. dollars and list the exchange rate used.

 

2.Travel and expense reports must be signed by the Employee and approved by the Employee’s manager before forwarding to accounting. Reimbursement will be made via the next scheduled check run, which should be within fifteen (15) days after the accounting department receives an approved travel and expense report.

 

3.In the event that the Employee owes the Company funds, the funds should accompany the completed travel and expense report. Any amounts due the Company and not paid will be deducted from any future payment requests.

 

4.Any expense submitted that does not comply with the guidelines of this policy will not be reimbursed, unless accompanied by a valid exception approved by the CFO, President or CEO.

 

Confidential – Consulting AgreementPage -9-

 

  

LODGING:

 

Employees are permitted to reserve hotel rooms for out of town travel. Neither luxury, nor sub-standard accommodations should be used. Employees will only be reimbursed for standard hotel rooms. No upgrades to suites are permitted. Saturday night stays are permitted, but not required, if the stay results in airfare savings in excess of the extra night(s) stay and meals. Where appropriate, Employees are expected to book their accommodations using conference hotels and discounts. It is the Employee’s responsibility to cancel reservations not expected to be utilized. The Company will not reimburse no-show fees.

 

AIRFARE:

 

Air travel will be via the most direct and economical means. Employees are expected to book their airfare as far in advance as possible – at least seven (7) days in most instances. Use of "Non-Refundable" airfare is recommended. (In most cases, if the travel must change or the trip is canceled all together, the funds can be used as a credit toward future travel, less a service charge imposed by the airline. Employees must include this credit on their next travel and expense report that includes air travel.) Employees may fly business class on international flights where in-flight time exceeds six hours in duration. Benefits from frequent flier memberships are considered to belong to the Employee. The Company does not reimburse any fees or dues associated with such memberships.

 

PERSONAL TRANSPORTATION/MILEAGE:

 

Employees with a valid driver’s license may submit expenses for the use of their personal car while on business. Employees will be reimbursed the standard IRS rate for every mile driven on behalf of the Company that exceeds their normal commuting mileage, defined as from the Employee home to the Company’s facility. Receipts should be submitted for any parking expenses or tolls.

 

RENTAL CARS:

 

Compact or midsize cars can be rented when having a car is deemed necessary (i.e., taxi cabs are not prevalent or the distance from the airport or hotel to the destination is excessive). When possible, every effort should be made to return rental cars with the proper fuel level. Receipts should be submitted for gas with the T&E report. Additional liability and physical damage insurance should be waived for cars rented in the United States as the Company’s travel insurance policy covers Company travel via rental cars. Employees renting cars should include the Company’s name somewhere on the rental agreement. Additional liability and physical damage insurance should be purchased from the rental agency for cars rented outside the United States.

 

Confidential – Consulting AgreementPage -10-

 

 

TRAIN FARE:

 

Train travel will be via the most direct and economical means. Employees are expected to book their train fare as far in advance as possible. Use of "Non-Refundable" train fare is recommended. The Acela express service, where all seats are business class, is permitted for travel between Boston and New York and DC. Employees may use first class train accommodations where on-train time exceeds seven hours in duration. Benefits from frequent traveler memberships are considered to belong to the Employee. The Company does not reimburse any fees or dues associated with such memberships.

 

TELEPHONE/FACSIMILES/INTERNET SERVICES:

 

Reasonable expenses incurred while traveling for telephone, fax, internet, and telegraph for Company business communications are reimbursable. Where applicable, Employees should use their Company issued cell phones when traveling and not incur extensive calls through their hotel rooms. Necessary business calls made from the Employee’s residence are reimbursable. A copy of the telephone bill and an explanation of the business purpose should be submitted with your travel and expense report.

 

BUSINESS MEALS AND ENTERTAINMENT:

 

Meals. Individual meals can be purchased while an Employee is traveling for approved business purposes. Individual meals will be reimbursed at the lower of $30 USD per meal or $50 USD per day.

 

When in the best interest of the Company, meals may be purchased for clients, affiliates, and others with whom the Company has business dealings. In addition, the government requires detailed record keeping legitimizing the expense. The items to be documented are:

 

 

Individuals present

 

Business affiliations

 

Location

 

Date

 

BUSINESS PURPOSE OF MEETING. This can be a short phrase such as “discuss new business”, “conduct employee review”, or “scientific discussions”

 

Reimbursements may include gratuities up to a maximum of 20%.

 

Entertainment. Entertainment expenses are generally not reimbursed by the Company. Entertainment expenses are only reimbursable with management prior approval. Pre-approved entertainment will only be reimbursed where an original receipt is submitted with the T & E report.

 

Confidential – Consulting AgreementPage -11-

 

 

NON-REIMBURSABLE EXPENSES, include but are not limited to the following:

 

Airline club or other travel memberships

 

Airline upgrade coupon booklets

 

Airline headsets

 

Sundries

 

Laundry services (unless a trip is unexpectedly extended)

 

Lost airline tickets applications

 

Mini-bar services

 

In room movies

 

Barber/Hair Stylist

 

Manicurist

 

Masseur/Spa services

 

Birthday or other celebration gifts

 

Unauthorized donations, contributions

 

Car insurance

 

Personal items other than emergency services items purchased while traveling because of lost or damaged baggage

 

Clothing purchases

 

Personal liquor or entertainment when not included in business dinner

 

Traffic violations and citations

 

Pet care, lawn care and snow removal while traveling

 

Theft, loss or damage to personal property

 

Cash advances and ATM fees

 

Daily newspapers while traveling

 

 

Confidential – Consulting AgreementPage -12-

 

EX-101.SCH 3 idra-20201229.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 idra-20201229_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 idra-20201229_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 tm211584d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000861838 2020-12-29 2020-12-29 iso4217:USD shares iso4217:USD shares 0000861838 false 8-K 8-K 2020-12-29 2020-12-29 Idera Pharmaceuticals, Inc. Idera Pharmaceuticals, Inc. DE 001-31918 04-3072298 505 Eagleview Blvd. Suite 212 Exton PA 19341 484 348-1600 false false false false false false false false Common Stock, par value $0.001 per share Common Stock, par value $0.001 per share IDRA IDRA NASDAQ NASDAQ false false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Cover
Dec. 29, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 29, 2020
Entity File Number 001-31918
Entity Registrant Name Idera Pharmaceuticals, Inc.
Entity Central Index Key 0000861838
Entity Tax Identification Number 04-3072298
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 505 Eagleview Blvd.
Entity Address, Address Line Two Suite 212
Entity Address, City or Town Exton
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19341
City Area Code 484
Local Phone Number 348-1600
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol IDRA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://iderapharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm211584d1_8k.htm idra-20201229.xsd idra-20201229_lab.xml idra-20201229_pre.xml tm211584d1_ex10-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm211584d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm211584d1_8k.htm" ] }, "labelLink": { "local": [ "idra-20201229_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "idra-20201229_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "idra-20201229.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "IDRA", "nsuri": "http://iderapharma.com/20201229", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "span", "b", "p", "body", "html" ], "baseRef": "tm211584d1_8k.htm", "contextRef": "From2020-12-29to2020-12-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://iderapharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "b", "p", "body", "html" ], "baseRef": "tm211584d1_8k.htm", "contextRef": "From2020-12-29to2020-12-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://iderapharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 14 0001104659-21-000926-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-000926-xbrl.zip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end